126 related articles for article (PubMed ID: 27460081)
1. G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma.
Huang XD; Xiao FJ; Wang SX; Yin RH; Lu CR; Li QF; Liu N; Zhang Y; Wang LS; Li PY
Tumour Biol; 2016 Oct; 37(10):13333-13343. PubMed ID: 27460081
[TBL] [Abstract][Full Text] [Related]
2. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma.
Keung EZ; Akdemir KC; Al Sannaa GA; Garnett J; Lev D; Torres KE; Lazar AJ; Rai K; Chin L
J Clin Invest; 2015 Aug; 125(8):2965-78. PubMed ID: 26193637
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic alteration of p16INK4a gene in dedifferentiation of liposarcoma.
He M; Aisner S; Benevenia J; Patterson F; Harrison LE; Hameed M
Pathol Res Pract; 2009; 205(6):386-94. PubMed ID: 19186005
[TBL] [Abstract][Full Text] [Related]
4. Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
Segura-Sánchez J; González-Cámpora R; Pareja-Megia MJ; García-Escudero A; Galera-Ruiz H; López-Beltrán A
Anticancer Res; 2006; 26(6C):4937-42. PubMed ID: 17214366
[TBL] [Abstract][Full Text] [Related]
5. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
6. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
7. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.
Zhang S; Yan L; Cui C; Wang Z; Wu J; Zhao M; Dong B; Guan X; Tian X; Hao C
Oncol Rep; 2020 Aug; 44(2):565-576. PubMed ID: 32627015
[TBL] [Abstract][Full Text] [Related]
8. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?
Le Guellec S; Chibon F; Ouali M; Perot G; Decouvelaere AV; Robin YM; Larousserie F; Terrier P; Coindre JM; Neuville A
Am J Surg Pathol; 2014 Mar; 38(3):293-304. PubMed ID: 24525499
[TBL] [Abstract][Full Text] [Related]
9. G protein pathway suppressor 2 suppresses gastric cancer by destabilizing epidermal growth factor receptor.
Si Y; Zhang H; Peng P; Zhu C; Shen J; Xiong Y; Liu X; Xiang Y; Li W; Ren Y; Wan F; Zhang L; Liu Y
Cancer Sci; 2021 Dec; 112(12):4867-4882. PubMed ID: 34609770
[TBL] [Abstract][Full Text] [Related]
10. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.
Hwang JA; Yang HM; Hong DP; Joo SY; Choi YL; Park JH; Lazar AJ; Pollock RE; Lev D; Kim SJ
Oncotarget; 2014 Oct; 5(19):9065-78. PubMed ID: 25238053
[TBL] [Abstract][Full Text] [Related]
11. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
12. The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma.
Sun R; Shen JK; Choy E; Yu Z; Hornicek FJ; Duan Z
Discov Med; 2015 Nov; 20(111):311-24. PubMed ID: 26645903
[TBL] [Abstract][Full Text] [Related]
13. Adipogenesis induces growth inhibition of dedifferentiated liposarcoma.
Kim YJ; Yu DB; Kim M; Choi YL
Cancer Sci; 2019 Aug; 110(8):2676-2683. PubMed ID: 31069877
[TBL] [Abstract][Full Text] [Related]
14. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1.
Chow WA; Guo S; Valdes-Albini F
Anticancer Drugs; 2006 Sep; 17(8):891-903. PubMed ID: 16940799
[TBL] [Abstract][Full Text] [Related]
15. Involvement of tumor suppressors PTEN and p53 in the formation of multiple subtypes of liposarcoma.
Puzio-Kuter AM; Laddha SV; Castillo-Martin M; Sun Y; Cordon-Cardo C; Chan CS; Levine AJ
Cell Death Differ; 2015 Nov; 22(11):1785-91. PubMed ID: 25822339
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of liposarcoma yields a multigene predictor of patient outcome and identifies genes that contribute to liposarcomagenesis.
Gobble RM; Qin LX; Brill ER; Angeles CV; Ugras S; O'Connor RB; Moraco NH; Decarolis PL; Antonescu C; Singer S
Cancer Res; 2011 Apr; 71(7):2697-705. PubMed ID: 21335544
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated fibroblasts promote the proliferation and decrease the doxorubicin sensitivity of liposarcoma cells.
Harati K; Daigeler A; Hirsch T; Jacobsen F; Behr B; Wallner C; Lehnhardt M; Becerikli M
Int J Mol Med; 2016 Jun; 37(6):1535-41. PubMed ID: 27082154
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of dicer and mir-155 expression in liposarcoma.
Vincenzi B; Iuliani M; Zoccoli A; Pantano F; Fioramonti M; De Lisi D; Frezza AM; Rabitti C; Perrone G; Onetti Muda A; Russo A; Giordano A; Santini D; Dei Tos AP; Tonini G
Oncotarget; 2015 Apr; 6(12):10586-91. PubMed ID: 25888631
[TBL] [Abstract][Full Text] [Related]
20. Functional genomics analysis reveals a MYC signature associated with a poor clinical prognosis in liposarcomas.
Tran D; Verma K; Ward K; Diaz D; Kataria E; Torabi A; Almeida A; Malfoy B; Stratford EW; Mitchell DC; Bryan BA
Am J Pathol; 2015 Mar; 185(3):717-28. PubMed ID: 25622542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
